#24: Patient selection and antiplatelet therapy for percutaneous coronary intervention (PCI), the best anticoagulants for patients with atrial fibrillation

#24: Patient selection and antiplatelet therapy for percutaneous coronary intervention (PCI), the best anticoagulants for patients with atrial fibrillation

In this episode of Medmastery's Cardiology Digest, we dive into three groundbreaking studies that are set to reshape our understanding and approach to cardiology.

STUDY #1: First, we discuss a landmark piece of research that sheds new light on the benefits of percutaneous coronary intervention for patients with significant coronary artery disease who need a transcatheter aortic valve replacement. This study addresses important questions about patient selection for this intervention.

Lønborg, J, Jabbari, R, Sabbah, M, et al. 2024. PCI in patients undergoing transcatheter aortic-valve implantation. N Engl J Med. Published online. (https://doi.org/10.1056/NEJMoa2401513)

STUDY #2: Next, we examine an insightful meta-analysis that evaluates patient-level data to inform the future of dual antiplatelet therapy after percutaneous coronary intervention. Discover the factors influencing the transition to ticagrelor monotherapy post-PCI and why this could change current guideline recommendations.

Valgimigli, M, Hong, S, Gragnano, F, et al. 2024. De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: A systematic review and individual patient-level meta-analysis of randomized trials. Lancet. 10456: 937–948. (https://doi.org/10.1016/S0140-6736(24)01616-7)

STUDY #3: Lastly, we take a closer look at the EPIC-CAD study, which aligns with previous findings from the AFIRE trial. Learn why anticoagulant monotherapy is now being considered for the majority of patients with atrial fibrillation who require anticoagulation and have stable coronary artery disease, and what this means for your clinical practice.

Cho, MS, Kang, D-Y, Ahn, J-M, et al. 2024. Edoxaban antithrombotic therapy for atrial fibrillation and stable coronary artery disease. N Engl J Med. Published online. (https://doi.org/10.1056/NEJMoa2407362)

Tune in to this episode for an engaging in-depth discussion of these studies and stay ahead in the ever-evolving field of cardiology!

Learn more with Medmastery's courses:

Percutaneous Coronary Intervention Essentials (6 CME)

Percutaneous Coronary Intervention Essentials Workshop (6 CME)

Get a Basic or Pro account, or, get a Trial account.

Show notes:

Visit us at https://www.medmastery.com/podcasts/cardiology-podcast.

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(25)

#25: Influenza and myocardial infarction, fasting protocols for cath lab procedures, anticoagulation therapy and transcatheter aortic-valve replacement

#25: Influenza and myocardial infarction, fasting protocols for cath lab procedures, anticoagulation therapy and transcatheter aortic-valve replacement

In today's episode of Cardiology Digest, we look at three recent research papers that can impact your clinical practice. They're from NEJM Evidence, the European Heart Journal, and The New England Jou...

8 Okt 202410min

#23: Edoxaban dosage and atrial fibrillation, invasive vs. noninvasive treatment of NSTEMI, chelation therapy for coronary artery disease

#23: Edoxaban dosage and atrial fibrillation, invasive vs. noninvasive treatment of NSTEMI, chelation therapy for coronary artery disease

Stay ahead with the newest cardiology research findings that could change your clinical practice! STUDY #1: First up, we explore new data on edoxaban dosage for older patients with atrial fibrillation...

10 Sep 202410min

#22: Heart failure & rapid uptitration of neurohormonal blockade, home treatment for acute pulmonary embolism, cardiovascular outcomes after bariatric surgery for weight loss

#22: Heart failure & rapid uptitration of neurohormonal blockade, home treatment for acute pulmonary embolism, cardiovascular outcomes after bariatric surgery for weight loss

Welcome to the latest episode of Medmastery's Cardiology Digest, where In less than 15 minutes we'll get you up to date on breakthrough studies and advancements in cardiology that can impact your clin...

27 Aug 202412min

#21: Semaglutide and blindness, antihypertensive medications and eczematous dermatitis, the new PREVENT cardiovascular risk calculator

#21: Semaglutide and blindness, antihypertensive medications and eczematous dermatitis, the new PREVENT cardiovascular risk calculator

This week, we have three compelling research papers that are sure to expand your clinical acumen. STUDY #1: We explore the debate surrounding the new PREVENT calculator's impact on predictions of 10-y...

13 Aug 202412min

#20: Comparing 2 cryoballoons for ablation of paroxysmal atrial fibrillation, a high-risk subpopulation for transcatheter aortic valve replacement, hypertensive disorders in pregnancy

#20: Comparing 2 cryoballoons for ablation of paroxysmal atrial fibrillation, a high-risk subpopulation for transcatheter aortic valve replacement, hypertensive disorders in pregnancy

In this episode of Cardiology Digest, we dive into top journals like JAMA Cardiology to bring you three of the most compelling recent research papers from the field of cardiology. STUDY #1: First, see...

30 Juli 202412min

#19:  Coffee's impact on blood pressure, safety of carotid artery stenting in the real world, transcatheter aortic-valve replacement in patients with coronary artery disease

#19: Coffee's impact on blood pressure, safety of carotid artery stenting in the real world, transcatheter aortic-valve replacement in patients with coronary artery disease

Ready to dig into the latest cardiology research? In less than 15 minutes, we'll give you the low-down on three new studies that'll help you in clinical practice. STUDY #1: First, we explore safety ou...

16 Juli 202410min

#18: CHA2DS2-VASc scoring and anticoagulation for silent atrial fibrillation, race and renin-angiotensin system inhibition in HFrEF, V142I transthyretin gene variant and cardiovascular health

#18: CHA2DS2-VASc scoring and anticoagulation for silent atrial fibrillation, race and renin-angiotensin system inhibition in HFrEF, V142I transthyretin gene variant and cardiovascular health

In less than 15 minutes, Medmastery's Cardiology Digest will give you the low-down on some of the most compelling studies in cardiology that clinicians with an interest in cardiovascular health need t...

2 Juli 202412min

Populärt inom Vetenskap

dumma-manniskor
p3-dystopia
angestpodden
allt-du-velat-veta
rss-ronden
doden-hjarnan-kemisten
rss-ufobortom-rimligt-tvivel
kapitalet-en-podd-om-ekonomi
rss-vetenskapsradion-2
paranormalt-med-caroline-giertz
medicinvetarna
rss-vetenskapsradion
halsorevolutionen
rss-spraket
hacka-livet
svd-nyhetsartiklar
det-morka-psyket
sexet
rss-experimentet
rss-kriminologerna